Liver disease starts more quietly than we thought: how molecular profiles expose early MASLD
Metabolic dysfunction-associated steatotic liver disease, MASLD, the new name for what used to be called "fatty liver disease," affects more than a billion people worldwide. Yet we know surprisingly little about the earliest molecular changes that drive its dangerous progression toward cirrhosis. A new study is starting to change that.
MASLD typically begins without any symptoms. Fat accumulates in the liver, but that alone does not necessarily cause serious damage. In some patients, however, the condition escalates into liver inflammation, fibrosis, and eventually cirrhosis, an irreversible stage where a transplant is the only option left. What determines which patients end up on that path remains largely unknown. That is partly a matter of biology, and partly a matter of data: liver tissue is difficult to obtain, and systematic molecular analyses of early-stage human MASLD are scarce.
An international team carried out exactly that kind of analysis, described in eLife. They collected liver tissue and blood samples from severely obese patients with no liver disease and from patients in the early stages of MASLD, then ran both transcriptomics (gene expression) and metabolomics (metabolite profiling) on all of them. The results reveal a striking disconnect: while the blood metabolome barely differed between the groups, the liver tissue itself already showed substantial molecular changes, long before any clinical symptoms appear.
The liver shifts while the blood stays silent
That is a crucial finding for clinical practice. Most MASLD diagnostics run through blood tests: liver transaminases, lipid profiles, insulin resistance markers. This study suggests that those blood results miss the earliest changes happening in the liver. By the time you look at the blood, the liver is already in a different molecular state than the readings would lead you to believe.
In the liver transcriptome, the researchers saw changes in pathways involved in fatty acid metabolism, immune activation, and stress response. Some of those patterns were recognizable from earlier studies in advanced MASLD, but here they were already present at early, clinically still relatively benign stages. That raises the question of whether therapeutic intervention at precisely that early phase, before fibrosis sets in, would be more effective than current practice, where patients typically are not treated until the disease has already progressed.
What this means for early diagnosis
The findings also point toward better biomarkers. If blood does not accurately reflect early liver changes, researchers need to look for other signals, possibly in liver-specific proteins, extracellular vesicles, or particular metabolites that do shift earlier. That is no trivial problem: a liver biopsy remains the gold standard but is invasive and is not performed routinely.
The study is not an endpoint but a molecular atlas, a thorough description of what happens in the liver during the earliest stages of a disease that now occurs on an epidemic scale. How that atlas translates into diagnostic tools or treatment strategies is a question that will require further research.